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ABSTRACT  
Prebiotic is a substrate that is selectively utilized by host microorganisms 
conferring a health benefit. The present study aimed to investigate the prebiotic 
potential of starch of Tinospora cordifolia (5% w/v) based on in vitro growth 
stimulation of Lactobacillus plantarum and Bifidobacterium bifidum, using 
individual strains and consortia. Bacterial cultures were incubated under 
anaerobic conditions with starch of Tinospora cordifolia (test) and with distilled 
water as the control. At various contact time points (0, 1, 48 and 96 hours), small 
aliquots were sampled. The organisms were plated on specific growth media 
under anaerobic conditions for Bifidobacterium and microaerophilic for 
Lactobacillus, and total viable count was determined by standard plate count. 
Starch of Tinospora cordifolia promoted growth of both bacterial strains, singly 
and in consortia. The mean log colony forming units (CFU) ± standard deviation of 
Lactobacillus in test was significantly higher in comparison to control (8.09±0.07 
vs 7.06±0.03, p<0.05) at 48 hours incubation, thereafter the growth of 
Lactobacillus plateaued through 96 hours. CFUs for Bifidobacterium in test were 
8.52±0.28 at 48 hours and 8.74±0.14 at 96 hours incubation, both significantly 
higher (p<0.005) when compared to control. Bifidobacterium in test exhibited 90-
fold relative increase in growth when compared to control. Lactobacillus being 
more robust showed an immediate increase in growth, while Bifidobacterium 
demonstrated a delayed but sustained growth, which extended over a period of 
time. These findings suggest that Starch of Tinospora cordifolia may enhance the 
gastrointestinal health of the host through modulation of overall composition of 
gut microbiota. 
INTRODUCTION
The human gastrointestinal tract harbors a diverse 
range of resident microorganisms, termed gut 
microbiota, which play a crucial role in health and 
disease of the host by maintaining immune and 
metabolic homeostasis, integrity of mucosal gut 
barrier and protecting against pathogens.1-
3Antibiotics, pathogens, dietary variations, exercise, 
hygiene practices, stress, depression, smoking, 
vaccinations, or several environmental factors can 
disrupt or alter the gut microbiome composition, 
thereby influencing the dominance of an organism 
under a particular circumstance.2,4-6 Altered gut 
bacterial composition (dysbiosis) has been 
associated with the pathogenesis of a variety of 
human diseases ranging from luminal diseases such 
as inflammatory bowel disease (Crohn’s disease and 
ulcerative colitis), metabolic diseases such as 
diabetes and obesity, allergic diseases, chronic 
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inflammatory diseases like rheumatoid arthritis and 
psoriasis to neurodevelopmental illness.7-10 The 
beneficial effects of the gut microbial genera, 
particularly Bacteroides, Eubacterium, 
Ruminococcus, Bifidobacterium and Lactobacillus, 
have been noted and modulation of gutmicroflora 
for growth of these beneficial microorganisms 
offers a promising therapeutic strategy in illness 
borne from the gutdysbiosis or “leaky gut”.11 
 Antibiotics are generally a choice of 
therapy for the treatment for gastrointestinal 
infections, however, increased antibiotic resistance 
and antibiotic-associated alteration in native gut 
microbiota are major concerns.12, 13 Probiotics are 
live microorganisms, which when administered in 
adequate amounts, confer a health benefit on the 
host.14Probiotics are bacterial supplements 
recommended for a variety of clinical reasons, 
including stimulating the immune system, 
protecting against cardiovascular or metabolic 
diseases, enhancing post-infectious health, and 
improving bowel function. Probiotics are effective 
only if they are in their viable forms and resistant to 
gastric acid, bile, and pancreatic enzymes.15 
 On the contrary, the concept of 
prebiotics is based on the strategy to improve 
health by restoring or favorably modulating one’s 
own gut microbiota composition. According to the 
current International Scientific Association for 
Probiotics and Prebiotics (ISAPP) consensus panel, 
prebiotic is defined as a substrate that is selectively 
utilized by host microorganisms conferring a health 
benefit.16 Prebiotics are non-digestible, non-
absorbable, and resistant to gastric acids and 
hydrolytic enzymes. They are fermented by gut 
microbiota and cause selective proliferation of the 
beneficial bacteria that already exist in the gut 
hence offering the benefits they inadvertently do. 
The effective combinations of antibiotic or probiotic 
with prebiotic supplement can produce sustainable 
changes in gut microbiota and can benefit the 
human host. 
About 40-90% of gut microorganisms are 
difficult to culturein the in vitro settings,17hence 
most of the in vitro studies related to the effects of 
prebiotics on the gut microbiota have been focused 
on the stimulation of Bifidobacterium and 
Lactobacillus.18-20Prebiotics are typically complex 
carbohydrates or dietary fibers, containing 
fructooligosaccharides, inulin and galactooligo-
saccharides, which encourage growth of these 
beneficial gut bacteria. These bacteria express 
carbohydrate-active enzymes, which facilitate 
fermentation of complex carbohydrates to generate 
short chain fatty acids (SCFAs) such as acetate, 
propionate and butyrate, which help in regulating 
immune system and inflammatory responses, and 
maintaining gut mucosal integrity. 
Tinospora cordifolia, an herbaceous vine 
(family:Menispermaceae) indigenous to the tropical 
areas of India, Myanmar and Sri Lanka, is widely 
used in ethnomedicine to treat various ailments 
related to immune-related diseases. An 
arabinogalactan is a highly branched, high 
molecular weight, purified polysaccharide isolated 
from stems of Tinospora cordifolia. Arabinogalactan 
serves as a non-digestible substrate for beneficial 
gut habitant bacteria assisting in their repopulation 
and is thus considered to be responsible for 
immunomodulatory activity.21,22 However, these 
ethnopharmacological uses are mainly with limited 
or without scientific evidence. A polyherbal 
formulation, commercially available as Somavit® 
(Millennium Herbal Care Ltd.) contains starch of 
Tinospora cordifolia as its key ingredient, and is 
recommended for its prebiotic activity. Thus, the 
present study aimed to investigate the prebiotic 
effect of starch of Tinospora cordifolia, based on the 
potential to stimulate the growth of Lactobacillus 
plantarum and Bifidobacterium bifidum in an in 
vitro setting. 
MATERIAL AND METHODS 
Sample preparation  
Test samples were prepared by weighing 0.75 gm of 
starch of Tinospora cordifolia and dispensing in 15 
mL of differential reinforced clostridial medium 
(DRCM) broth to achieve 5% w/v concentration in 
each test tube, while control samples were 
prepared in a similar manner by replacing starch of 
Tinospora cordifolia with 0.75 mL of deionized 
distilled water. 
Bacterial strains and growth conditions  
Two standard test organisms, Lactobacillus 
plantarum (American Type Culture Collection 
[ATCC] 8014) and Bifidobacterium bifidum (ATCC 
11863) were selected as representative resident gut 
microflora. The Lactobacillus and Bifidobacterium 
cultures were maintained in glycerol stocks at -80ºC 
and subcultured on specified growth agar medium. 
Bifidobacterium strain was grown on DRCM agar 
under anaerobic conditions at 37ºC±1ºC for 5 days 
and Lactobacillus strain was grown on de Man, 
Rogosa and Sharpe (MRS) agar 30ºC±1ºC for 48 
hours under microaerophilic conditions. Cell 
suspensions of Lactobacillus and Bifidobacterium 
cultures were prepared to have a cell density of 
1.0×105 to 3.0×105colony forming units (CFU)/mL. 
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Quantitative determination of growth in 
bacterial count: prebiotic effect 
Three systems of each, test and control (Table 1), 
(all in triplicates) were prepared to evaluate the 
effect of 5%w/v starch of Tinospora cordifolia 
(test)on the individual bacterial strains of 
Bifidobacterium and Lactobacillus, and in consortia 
of both these strains. Bacterial suspension was 
added to the respective system, homogenously 
mixed and the viable counts of the test cultures 
were immediately determined which represented 
the 0 hour counts. Thereafter, all the systems were 
incubated under anaerobic conditions at 37ºC ± 1ºC 
for up to 96 hours and sampled at the above defined 
contact times. 
Growth promotion by starch of Tinospora 
cordifolia was evaluated by determining the 
bacterial population using 10-fold serial dilutions 
and standard platecount method. At all contact 
times, including the 0 hour sample, 1 mL of 
inoculated sample from both test and control 
systems were analyzed by carrying out 10-fold 
serial dilution up to 10-8 and plating each dilution 
on specific growth agar medium using spread plate 
technique. All the plates were incubated at 
conditions specified for optimum growth of test 
strains used in the study (Table 1), and bacterial 
colonies were enumerated (Figure 1). 
Statistical analyses 
Descriptive results were presented as mean ± 
standard deviation (SD). Paired t-test was applied 
to the data using Microsoft office excel, the p-values 
<0.05 were considered as significant.  
Results 
Starch of Tinospora cordifolia (5%w/v) showed 
greater than 1 log difference in mean CFU/mL of 
Lactobacillus plantarum and Bifidobacterium 
bifidum following 48 hours incubation. The mean 
log colony count ± standard deviation (SD) of 
Lactobacillus was 8.09±0.07 in test, which was 
significantly higher (p<0.05) when compared to 
control (7.06±0.03) at 48 hours, thereafter the 
growth of Lactobacillus plateaued in both the 
systems through 96 hours. The mean log colony 
count of Bifidobacterium in test was 8.52±0.28 at 48 
hours and 8.74±0.14 at 96 hours, which were 
significantly higher (p<0.005) when compared to 
control. Furthermore, Bifidobacterium continued to 
grow in contact with starch of Tinospora cordifolia 
even after 96 hours of incubation (Figure 2). 
Relative difference in bacterial populations 
between the control and the test system was 
calculated to demonstrate the effect of starch of 
Tinospora cordifolia on the growth of test strains at 
a given contact time. Bifidobacterium bifidumin 
contact with starch of Tinospora cordifolia, at the 
contact time of 48 hour exhibited 90 percent 
relative increase in growth when compared with 
control, while in the consortium system, 
Lactobacillus plantarume xhibited better growth. 
The relative growth of Lactobacillus plantarum at 
the end of 48 hour contact time with starch of 
Tinospora cordifolia was found to be 70 percent as 
compared to 26 percent in its control system 
(Figure 3). 
DISCUSSION 
Probiotics and prebiotics are extensively studied to 
understand their influence and role on the gut 
microbiota.23Probiotics colonize the human 
intestine transiently which necessitates frequent 
dosing to maintain biologically significant numbers 
of probiotic strains. Also, there are variations across 
the gut microbiome of the host that would either 
resist or facilitate the colonization intended by the 
probiotic.24 The clinical outcome of probiotic varies 
from one person to another since the number of 
viable bacteria populating or colonizing the 
intestine depends on several factors other than 
dose; including type of probiotic formulation, co-
administration of food or milk, and the host’s 
gastric pH, intestinal motility, adherence to 
intestinal epithelium and prior composition of gut 
microbiome. This was revealed in studies where the 
fecal recovery and biopsy microbiome analyses of 
the host were not equivalent after administration of 
probiotic. 
In contrast, prebiotics are non-digestible, 
non-absorbable substrates that serve as food for 
existing gut microbiome towards a sustained 
healthy composition. Although probiotics are 
recommended by clinicians in a wide range of 
diseases, a polyherbal prebiotic like Somavit® might 
provide a host-centric delivery approach. In the 
present study, starch of Tinospora cordifolia, the 
principle ingredient of Somavit® was studied for its 
role as a prebiotic. Majority of studies have focused 
on pure oligosaccharides, including inulin, 
fructooligosaccharides, galactooligosaccharides, 
xylooligosaccharides, starch etc. for their prebiotic 
potential.20, 25 The prebiotic potential of blueberry, 
pomegranate, almond skin, and red grape extracts 
on Lactobacillus and Bifidobacterium species have 
been assessed.26-29 Furthermore, a study has 
reported the prebiotic effects of Tulsi, Ginger, and 
Black pepper using cultures of Lactobacillus 
rhamnosus GG and Bifidobacterium infantis.30 
 In the current study, the prebiotic 
potential of starch of Tinospora cordifolia was 
studied based on its influence on the growth of 
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Bifidobacterium bifidum and Lactobacillus 
plantarum, singly and their consortia. The use of 
consortia of Lactobacillus and Bifidobacterium for 
assessment of prebiotic potential supports the 
symbiotic behavior of these cultures. The entire 
contact study was conducted under anaerobic 
conditions to mimic the growth conditions in their 
natural ecosystem. The viable growth was assessed 
under anaerobic conditions for Bifidobacterium and 
microaerophilic conditions for Lactobacillus. 
Furthermore, since the Ayurvedic preparation 
tends to sediment to the base of the liquid medium, 
the entire study was conducted in a controlled 
liquid interface to facilitate uniform contact of the 
prebiotic. The study explored comprehensively the 
impact of starch of Tinospora cordifolia on the 
response of bacterial population studied 
individually and in consortium for the period of 
1hour, 48hours and 96hours, which aligns with the 
time required for invitro multiplication and 
visualization of growth outcome by the chosen 
bacterial strains and the maximum time period that 
the prebiotic may remain in the gut.  
This study inferred that the beneficial roles 
of both these organisms possibly proceed in a 
deferred manner; Lactobacillus being more robust 
exhibited a rapid growth in bacterial population, 
while Bifidobacterium displayed a delayed growth. 
Growth of Lactobacillus promotes enhancement of 
Bifidobacterium, allowing it to sustain for a longer 
duration in the human gut. The distinctive 
observation was the increase in count of 
Bifidobacterium even after 96 hours of contact time. 
These observations indicated the sustenance of 
these beneficial bacterial populations, which may 
help in reducing the dosing frequency of the 
prebiotic. These results suggest that the growth 
modulation of these bacterial populations with 
starch of Tinospora cordifolia could offer the desired 
benefits over an extended period of time. 
CONCLUSION  
In conclusion, starch of Tinospora cordifolia, a key 
component of Somavit® demonstrated a 
considerable growth stimulatory activity by 
increasing the population of beneficial gut 
microorganisms, Bifidobacterium bifidum and 
Lactobacillus plantarum in vitro and thus, 
confirmed a high prebiotic potential for this 
polyherbal formulation. Furthermore, a sustained 
growth modulation offered could probably reduce 
the dosing frequency. However, in order to 
substantiate the present in vitro data, further 
clinical studies to establish the prebiotic effect of 
starch of Tinospora cordifolia are warranted. 
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Table 1: Summary of different bacterial systems, their growth conditions and growth characteristics 
Set No System Growth condition Colony characteristics 
1 
CONTROL- Lactobacillus 
plantarum 
MRS agar, 30oC ± 1ºC, 48 hours, 
microaerophilic 
For Lactobacillus 
plantarum: Circular, 
convex, with entire edge 
smooth, and 1mm-2mm 
in size 
 
For Bifidobacterium 
bifidum: Circular, flat, 
dull, and in different 
sizes 
2 
TEST- Lactobacillus 
plantarum 
3 
CONTROL-Bifidobacterium 
bifidum 
DRCM agar, 37oC ± 1ºC, 5 days, 
anaerobically 
4 
TEST-Bifidobacterium 
bifidum 
5a 
CONTROL-Consortium of 
Lactobacillus plantarum 
andBifidobacterium bifidum 
For Lactobacillus plantarum: MRS 
agar, 30oC ± 1ºC, 48 hours, 
microaerophilic 
For Bifidobacterium bifidum: DRCM 
agar, 37oC ± 1ºC, 5 days, 
anaerobically 
6a 
TEST- Consortium of 
Lactobacillus plantarum 
andBifidobacterium bifidum 
aConsortium systems were incubated in both the growth conditions separately for enumeration of 
Lactobacillus and Bifidobacterium colonies. TEST (containing 5% w/v starch of Tinospora cordifolia) and 
CONTROL (containing distilled water) systems were inoculated with cell suspensions of test strains of cell 
density of 1 x 105 to 3 x 105. Abbreviations: MRS agar: de Man, Rogosa and Sharpe agar; DRCM: Differential 
reinforced clostridial medium. 
Figure legends 
Figure 1: Representative plates of growth of (A) Lactobacillus plantarum on MRS agar and (B) 
Bifidobacterium bifidum on DRCM agar at sampling point of 48 hour 
(A) observed in viable counts performed for Test and Control sets at 10-fold serial dilution of 1:100000 
(1:10-5) after 48 hours of incubation under microaerophilic conditions; (B) observed in viable counts 
performed for Test and Control sets at 10-fold serial dilution of 1:10000 (1:10-4) after 5 days of incubation 
under anaerobic conditions. Abbreviations: MRS agar: de Man, Rogosa and Sharpe agar; DRCM: Differential 
reinforced clostridial medium 
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Figure 2: Growth of bacterial strains (A) Lactobacillus plantarum (B) Bifidobacterium bifidum, 
expressed as average bacterial count in terms of Mean log10 CFU/mL with increase in contact time 
with Test (5%w/v Tinospora cordifolia) and Control (5%w/v distilled water) 
Test: 5% w/v starch of Tinospora cordifolia; Control: 5% w/v Distilled water. Abbreviations: B.bifidum: 
Bifidobacterium bifidum; CFU: colony forming units; L.plantarum: Lactobacillus plantarum; SD: standard 
deviation 
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Figure 3: Relative percent increase in bacterial growth when in contact with the starch of Tinospora 
cordifolia as compared to control 
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